Archive

What SLU-PP-332 actually is, how the Burris laboratory's Nature Metabolism 2023 research demonstrated ERR alpha and ERR gamma activation driving mitochondrial biogenesis and endurance in animal models, why there is currently no human data, and where it fits alongside SS-31, NAD+, and MOTS-C in a mitochondrial protocol.

What the glucagon receptor adds to GLP-1 and GIP agonism, why the energy expenditure mechanism makes retatrutide mechanistically distinct from tirzepatide, what the phase 2 trial data actually showed, and how the investigational status shapes the clinical conversation around its use.

What SS-31 actually is, how it concentrates at the inner mitochondrial membrane to protect cardiolipin and stabilize the electron transport chain, what the cardiac and skeletal muscle research shows, and why its mechanism addresses a specific point of mitochondrial failure that NAD+ and MOTS-C do not.

The mechanisms behind DSIP, Epithalon, Semax, Selank, and the DSIP/BPC-157/CJC-1295 combination stack, why sedation is not sleep optimization, and how each compound addresses a distinct dimension of sleep architecture, circadian regulation, and overnight recovery.

What peptide bioregulators are, how their epigenetic gene regulation mechanism differs from signaling peptides, what Cartalax does for cartilage and connective tissue, and why decades of Russian research on this compound class has gone largely unnoticed in Western optimization.